Permanent implantation of I-125 and Pd-103 seeds is one of the widely used treatment options for the early stage prostate cancer with minimum normal tissue complications and long-term local control of the tumor. This is possible because of several technological advances made in the past decade to better understand the procedural aspects of implantations with the desired clinical outcome and with acceptable morbidities. In addition, with the widespread use of PSA testing, more widely disseminated information about prostate cancer and increased patient awareness, over 70% of patients are diagnosed early with localized disease and therefore are candidates for definitive local therapy. Delineation of soft tissue structures including the prostate, rectum, urethra and bladder has become more accurate with the use of imaging modalities including Ultrasound and MRI, with or without the CT. A re-evaluation of the dosimetric parameters of the radioactive sources has lead to a more precise estimate of the dose delivered to the prostate and the associated critical normal structures. Technological improvements in the post implant dosimetry have helped to understand the factors, which makes an implant a "good implant" or a "poor implant".
Introduction
3D conformal transperineal prostate brachytherapy is currently performed using I-125 or Pd-103 under 3D Ultrasound and template guidance, either as a single treatment modality or in combination with external beam radiation therapy (XRT). Many reports have been published to evaluate and compare the results with implant therapy with those of radical prostatectomy and XRT. Health related quality of life, long-term local control and rates of urethral and rectal toxicity and acceptable rates of sexual dysfunction are comparable or even better with prostate brachytherapy (1-9). In addition, compared to a 7-9 weeks of XRT or prostatec-tomy requiring at least a few days of hospital stay, prostate brachytherapy has several advantages: i) it is performed as a one day out-patient procedure or with a maximum of one day stay in the hospital, ii) avoids morbidity of laparotomy, iii) recovery is faster and patient can return to work life earlier, and iv) it is well tolerated by older patients (10) (11) . The achievement of long term biochemical control with low morbidity and improvements in quality of life through prostate brachytherapy became possible because of the following technological advances since the dawn of prostate brachytherapy: i) the development of I-125 and Pd-103 seeds, ii) new imaging techniques including TRUS, CAT scan and MRI, iii) computer based brachytherapy treatment planning, iv) intraoperative planning with real time verification of seed deposition and dose distribution, v) CT and MRI based evaluation of postimplant dose distribution in the prostate and critical normal tissues and vi) better understanding of volume-dose characteristics for local control and normal tissue toxicity.
The Dawn of Prostate Brachytherapy
Prostate brachytherapy has drawn the attention of physicians as a treatment modality about 90 years ago (12). Availability of domestic sources of radium set the stage for Hugh Young (13) and Benjamin Barringer (14) to pioneer radium therapy for urologic tumors. The transurethral brachytherapy using radium was more toxic to the urethra and not adequate to treat the prostate gland. To reduce the dose to the urethra and to increase the dose to the prostate, Young (13) used dose delivery to prostate through rectum, bladder and urethra. His system of rotation of implant sites and avoidance of site reirradiation would be the first technical advance in prostate brachytherapy.
Next advance was to develop and use radon gas sealed in gold capillaries with much shorter half-life than radium (14, 15) . Radon-bearing needles were passed through the perineum and into the prostate and needle positions were changed after 4-6 hours (14, 15) . Permanent implants were performed using radon in glass and later in gold capillary tubes with 3 mm length and 0.3 mm diameter, with an implanted activity of 50-100 mCi (14, 15) . The short-range beta particles delivered through the glass tube produced unacceptable tissue necrosis. Development of gold encapsulated seeds filtered the short-range radiation and the exiting gamma rays were more penetrating. The 6 mm gold seeds each containing 1.5 to 2 mCi of radon delivered 4000 mCi-h in a typical implant.
The Dark Ages
Brachytherapy did not gain popularity and was abandoned because of 3 main reasons; i) only a few patients remained free of disease after brachytherapy, ii) radiation safety concerns and iii) lack of aids to directly visualize the seeds and the ability to achieve satisfactory seed and dose distribution. Brachytherapy was replaced by surgery for disease confined to the prostate and castration for palliation of locally advanced disease for the next few decades (12).
Middle Ages
The unacceptable normal tissue morbidity with radium brachytherapy lead to the realization that more locally acting radiation sources would be needed to reduce the toxicity. This lead to the next technical advance in developing the radioactive gold in the form of colloidal solution, or gold seeds, with a short half life of 2.7 days, with the emission of short-range beta radiation and gamma radiation with a relatively high dose rate (12, 15) . Gold seeds were used either as a monotherapy or in combination with XRT. Although the results with gold seeds were comparable to that of XRT, the radiation exposure hazards associated with the use of high energy gold seeds was discouraging and did not gain popularity.
The development of low energy I-125 radioactive seeds was the next technical advance in the prostate brachytherapy (16). The use of I-125 seeds, with a half life of 60 days and with an average energy of 28 KeV was not only an ideal isotope for slow growing prostate cancer but also reduced the radiation safety concerns to a large extent (11, 12) . Although I-125 was perfect for prostate brachytherapy, the retropubic implantation technique was far from the ideal one. With the retropubic approach, a homogeneous distribution of the seeds in the prostate gland could not be achieved. While the results with I-125 were comparable to those of XRT for low to moderately differentiated tumors, the complications and morbidity were far from acceptable (12, 16, 17) . The intraoperative and postoperative complications with retropubic implantation of I-125 seeds included dysuria, incontinence, proctitis, impotence, nerve injury, excessive bleeding, lymphoceles, hematomas and abscesses. Although I-125 seeds were ideal for prostate brachytherapy, because of poor long term clinical results and the unacceptable morbidity seen with the retropubic approach, prostate brachytherapy was still limping in the early 1980s and nerve-sparing prostatectomy was available as a treatment option (12).
The Renaissance
The advent of new technologies made prostate brachytherapy less toxic to normal tissues and more effective in tumor eradication. Pd-103 seeds with shorter half-life and with rapid dose delivery and transrectal Ultrasound (TRUS) became available in late 1980s. On the clinical front the widespread use of TRUS and ease of biopsy plus PSA leading to the greater diagnosis of T1C disease played a significant role in the advancement of prostate brachytherapy. On the technological front, the concept of image-guided brachytherapy was introduced. This new technology helped to visualize the prostate gland and in the guidance of needles and seeds through transperineal approach and resurrected brachytherapy as a primary curative treatment modality with reduced morbidity and potential long-term clinical control (11, 12, 18) .
The Role of TRUS, CT, MRI and Fluoroscopy Technologies in the Pre-implant Treatment Planning
At present, pre-implant planning includes: i) the determination of the prostate volume, ii) selection of the isotope, iii) total activity estimation and radiation dose distribution planning and iv) developing a custom template based on preplan dosimetry or a universal template (20-23). Currently, TRUS, CT and MRI imaging techniques are being used to delineate the shape, size and volume of prostate, and the volumes of rectum, urethra and bladder for pre-implant treatment planning and dosimetry. The major task of preplanning is to estimate the precise volume of the prostate and the organs at risk. Estimation of the accurate volume of prostate gland is of paramount importance because the amount of radioactivity to be used to treat the gland with prescription dose is volume based. Any inaccuracy in volume estimation can lead to either overdosing or under-dosing the prostate. Similarly precise volumes of rectum, urethra and bladder are needed to estimate and limit the dose to these critical normal structures (20-23).
Although there are basic differences in the images obtained by these three modalities, the information obtained from these modalities is complimentary to each other ( Fig. 1 ). TRUS and MRI images have better contrast between soft tissues, which enable one to delineate the volumes of structure more accu-rately (24-29). However, MRI cannot provide electron density map for accurate dose calculations (in case of XRT) and is unable to accurately image complex bone/air regions and metallic objects such as seeds. With CT images, soft tissue contrast is poor and accurate localization of the prostate could be quite uncertain (28, 29) . This can lead to large inaccuracies in the estimation of prostate volumes using CT images. The volumes of prostate estimated using CT images has been observed to be higher by 10-50% than volumes estimated by TRUS or MRI (24-29). CT images provide a better contrast between objects varying in density, such as bone, seeds and air. A fusion of CT and MRI images is shown in the bottom right of Figure 1 , which helps to delineate the structures better.
Isotopes for Implant
I-125 and Pd-103 are the two isotopes currently being used for prostate brachytherapy (19, (30) (31) (32) (33) (34) (35) (36) . I-125 has a half-life of 60 days with an average energy of 28 keV and with an initial dose rate of 7 cGy/hour for a prescription dose of 140 Gy. Pd-103, with an average energy of 21 keV, has a halflife of 17 days. Its initial dose rate is 21 cGy/hour to deliver a prescription dose of 110 Gy. There are contentions that Pd-103 may be more effective in eradicating faster growing tumors (poorly differentiated/high grade) than I-125 because of its higher dose rate than that of I-125 (33-34). Retrospective studies have not shown a consistent difference in cure (biochemical survival) rates (31-35).
While Pd-103 and I-125 are equal in their effectiveness, Pd-103 may be less toxic to normal tissues. Walner et al. (31, 35) have observed that in patients treated with Pd-103, uri-nary symptoms resolved more quickly, recovery from prostatitis was sooner than in those treated with I-125 and there was a trend towards greater morbidity with I-125 than with Pd-103, most markedly at 6 months post-implant. These differences may reflect slight differences in acute morbidity between I-125 and Pd-103 treatments. Merrick et al. (36) have shown that the percentage volume of prostate receiving at least 100% of the prescription dose (V100) of I-125 implants was greater than that of Pd-103 but concluded that the difference was not substantial.
Estimation and Distribution of Total Radioactivity
Open retropubic implant technique used a nomogram developed by Anderson to determine the amount of radioactivity to be implanted and was based on the average dimension of the prostate (37). The average dimension is defined as one-third of the sum of the dimensions of the implant in three mutually perpendicular directions (37, 38). The nomogram was designed to deliver a matched peripheral dose (MPD) of 160 cGy for I-125. The MPD represents the dose covering a volume equivalent to an ellipsoid defined by three orthogonal measurements. Although the nomograms do not take into account of the non-uniform placement of seeds, they continue to be useful tools for predicting the total required activity for volume implants and for performing an independent check of the activity generated by computer optimization (39).
The average dimension method has been used to estimate the prostate volume during the early period of TRUS guided implantation (37, 38). Later it was shown that ellipsoid volume estimation method may underestimate the prostate volume by 10-50% compared to that estimated from the volumes contoured in serial transverse cuts obtained during TRUS (22). Currently, majority of the institutions estimate the prostate volume using TRUS or CT images and estimate the total activity using nomogram, lookup tables or treatment planning systems (19, (21) (22) (23) 26) .
Dose optimization treatment planning systems are used to determine the appropriate source positions to achieve the desired dose distribution before the day of implant. Not only the precise estimation of prostate volume but also the pattern of loading of the seeds can have a profound effect on the dose distribution in the prostate and dose to the urethra and anterior rectal wall (5, 7, 19, 21, 22, 40) . A strict uniform distribution of seeds results in higher central and urethral dose. Currently, computer-planning programs take into consideration a modified peripheral loading of seeds as the choice of source distribution within the prostate. In this technique, 60 to 70% of seeds or activity are implanted peripherally and the remaining seeds are implanted centrally, avoiding the urethra. This type of distribution limits the urethral dose to an acceptable level of 120 to 150% of the prescribed dose. However, these methods have a high probability of delivering higher dose to neuro-vascular bundle because of peripheral loading of 60-70% of activity. Therefore, it would be necessary to document the dose to the neurovascular bundle, crura and penile bulb in patients treated with either monotherapy or combined therapy. This would help to better understand the relationship between erectile dysfunction (ED) and dose to the neurovascular bundle, crura and penile bulb (41-45), as presented under postimplant dosimetry section.
The Techniques of Implantation
TRUS and fluoroscopy guided permanent interstitial seed implantation techniques revived the interest in prostate brachytherapy and established the technique as a viable treatment modality (18). A typical scenario of the implant technique under the guidance of TRUS and the template is shown in Figure 2 . Since then a few modifications have been described in the literature (5, 20-23, 27, 29, 40) . Some implant techniques were based on TRUS or CT image based pre-implant planning followed a few days later by TRUS and fluoroscopy guided seed implantation. In this technique, more time is available to optimize the dose distribution in terms of isodose coverage to prostate as shown in Figure 3 . In addition, a DVH can be generated with desired dose coverage to prostate in terms of D90 and other dosimetric parameters (Fig. 4) .
In this preplan technique, the patient position and the relationship between the prostate, rectum, bladder and urethra on the day of pre-implant CT and on the day of implantation could be different. In addition, prostate may undergo volume changes in the interval between planning and implantation. Therefore, TRUS based pre-implant volumes and dosimetry may not represent that of those on the day of implant.
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Nori et al. The recent interest has been to use the intraoperative planning approach for prostate brachytherapy. This approach combines the intraoperative planning, real-time on line dosimetry and the implantation of the seeds under the guidance of TRUS, and fluoroscopy or interventional magnetic resonance imaging (40, (48) (49) (50) . Some of the set backs with the preoperative implant technique can be overcome by this technique (23, 49) . In this technique, the position of the patient and the organs remains the same during planning and implantation. This can reduce the errors in prostate volume estimation and seed strength estimations and seed placement errors associated with the differences in the positions of prostate, rectum and bladder between pre-implant patient position and the position of the patient on the day of implant (20, 23, 40, (48) (49) (50) .
In the intraoperative planning and treatment technique, the patient is anesthetized and setup for implant in a modified exaggerated lithotomy position (48). Prostate is stabilized with implantation needles. TRUS images of the prostate were obtained in the implant position at 5 mm intervals and were sent to the brachytherapy-planning computer. The volumes of prostate, urethra and rectum are contoured. Then the brachytherapy planning system is used to generate optimized dosimetric plan with DVH for prostate, and normal structures. This optimized plan is summarized by the computer in terms of the template position, the offset from the prostate base, and the number of seeds of each needle (48). The physicist and the radiation oncologist review this plan in the treatment room before the seed implant takes place. Implantation needles were placed according to the intraoperative plan as confirmed by real-time TRUS. Seed deposition is carried out using the Mick applicator and verified by realtime TRUS images. Real time seed positions can be visually verified with the use of TRUS and fluoroscopy and radiographs against the plan seed position. If such visual inspections revealed regions of inaccurate seed placement and potential cold spots, the planning system can be used to place seeds to cover the cold spots.
Post-implant Dosimetry
Figures 5 and 6 show the relationship between prostate with seeds and rectum and bladder. Rectum, bladder, urethra, NVB, penile bulb and crura are the critical normal structures associated with seed implant. Implant quality and the out come of treatment in terms of tumor control and normal structure toxicity depends on the doses received by these organs (2, 21, 23, 27, 38, (41) (42) (43) (44) . Therefore, post-implant dosimetry plays a paramount role in evaluating the dose to prostate, rectum, urethra, NVB, bulb of the penis and crura.
In the past, post-implant dosimetry was traditionally performed using several radiographs and to see the dose distribution in 2D (19, 23). This technique was not adequate to analyze the dose distribution in 3D. Currently it is carried out in 3D using post-implant CT images (Fig. 6 ) or MRI (47) or CT and TRUS images or fusion of CT and MR images (19, 23, 25, (51) (52) (53) . The information given by CT and MR images is complimentary to each other. Therefore, a fusion between postimplant MR and CT images would help to better delineate the volumes of prostate, rectum urethra, NVB and penile bulb (MRI) and localization of high density seeds (CT) and in tern would lead to more accurate postimplant dosimetry. Refinements in co-registration of CT and MR images are needed to realize the full potential of this technique.
DVH is used to derive the implant quality parameters such as D100, D90 and D50, V100, V150, and V200, which help to understand the dose heterogeneity and conformity in the prescription volume (23, 27, 31, 35, 38) . Figure 4 (bottom) shows a typical post-implant DVH plot for prostate. DVH are also used to estimate the dose to the anterior rectal wall to understand the risk potential for rectal complications (1-3). Snyder et al. (3) have shown that the rectal volume thresholds associated with <5% risk of grade 2 proctitis at 5 years decreases with the increase in the dose to rectum as reproduced in Figure 7 .
Despite improved implant techniques and best experience and intentions, desired dose distribution may not be achieved in a few patients as shown by the post-implant dosimetry. Several factors can influence the quality of the implant: i) skill and experience of the Radiation Oncologist, ii) anatomical constraints such as pubic arch interference, iii) errors in seed placement, iv) post-implant edema, and v) time of postimplant dosimetry, to name a few (19, 27, 23, 33) . Postimplant dosimetry can help to identify implants with unacceptable dose coverage (19, 27, 23, 33) . In such cases, patient can be evaluated for further external beam therapy or a second seed implant (48, (54) (55) (56) . Now with the advent of IMRT, one may be able to differentially boost the inadequately covered areas in the prostate and achieve a desired dose distribution. Nath et al. (32) have shown a strong correlation of 3D volume-dose parameters to the local control rate and emphasized the importance of dosimetric adequacy of prostate implants. They have examined the relationship between 3D dosimetric parameters of patients implanted with I-125 seeds by retropubic approach. They have used cut-off values based on 3D dosimetry to separate patients with poor implants vs. good implants and implant outcomes. They found a strong correlation between 3D volume dose parameters and local control rate. Those patients with variables below the cut off values had poorer clinical out comes and vice versa. Similarly, the dose-response study reported by Stock et al. (57) for prostate implants with I-125 seeds further substantiated the role and importance of 3D postimplant dosimetry analysis. They have shown that the freedom from biochemical failure was dose dependent and increased as the dose to 90% of prostate (D90) increased.
They have provided evidence for a dose response at 140 Gy and concluded that an adequate I-125 implant should deliver a dose of 140-160 Gy as measured by the D90 using TG43 dosimetry guidelines (Fig. 8, reproduced from ref. 57) .
Postimplant dosimetry has also helped to understand the relationship between dose to neurovascular bundle (NVB), penile bulb and crura and erectile dysfunction (ED) after seed implant for prostate cancer (41) (42) (43) (44) . DiBiase et al. (41) have shown that the average doses to NVB with Pd-103 implant ranged from 150-260 Gy, and for I-125 implants, the average doses to NVB ranged from 200-325 Gy. In addition, they observed that 3 patients who developed early postimplant impotence had maximal NVB doses that far exceeded the average doses (>400 Gy) (41). Merrick et al. reported average NVB doses of 201% of prescription dose for I-125 and 230% of prescription dose for Pd-103 (42). In another report by Wright et al., the median dose to 50% of right and left NVB were 124% and 106% of the prescribed dose, respectively (45). In both cases, no relationship was found between radiation dose to NVB and the development of postimplant ED (42-45). However, the finding that doses more 400 Gy to NVB could cause impotency (41) leaves the possibility that higher does to NVB would induce ED in prostate brachytherapy patients, which is more likely with peripheral loading than with other types of loading of seeds.
A few reports have concluded that the bulb of the penis is an important anatomic structure involved in ED and that radiation damage to the bulb is very likely to be responsible, at least in part, for postimplant ED (43-45). Recent data supports this contention that doses to the penile bulb, rather than the doses to NVB are more likely associated with ED (43-46). Merrick et al. have concluded that the doses to 50% and 25% of penile bulb should be kept below 40% and 60% and doses to the 50% and 25% of crura should be maintained below 28% and 40% of the prescribed dose, respectively, to maximize postimplant potency (43, 46) . The observation by Wright et al. (44) support the conclusion of Merrick et al. (43, 46) . Refinements in the seed implant techniques, including preplanning and intraoperative seed placement will result in reduced doses to the proximal penis with improvements in potency preservation (44, 46) .
Radiation Safety
Radiation safety precautions are explained and written guidelines are given to the patient at the time of implantation. Guidelines advise the patients to avoid prolonged contact with children under the age of 18 and pregnant women for 2 months for Pd-103 and 6 months for I-125 implants. After the implant the patient may sleep with his wife and have sex after a few weeks wearing a condom. Condom protects from transferring any dislodged seeds into the vagina. Patients also wear a medicalert wrist bracelet for the duration of the radiation precaution (10,11). Radiation safety parameters following I-125 and P-103 implantation of prostate has been studied (58-59). They have concluded that patients and public need not be concerned about the patients being a radiation risk to the general public (58) and that radiation exposure to family members from a patient receiving a permanent prostate implant with I-125 and Pd-103 is very low and well below the limits recommended by the US Nuclear Regulatory Commission (59).
Future Directions
Brachytherapy alone or in combination with IMRT will remain as one of the three best treatment options for enhanced local control and improved quality of life. Adequate implant dose to 90% of prostate and understanding where to combine IMRT and BRT to homogenize the dose to the entire prostate in cases of inability to determine the exact extent of disease are also important issues to be addressed (60-63). Patient selection for brachytherapy or in combination with external beam radiation should be based on careful risk identification in terms of PSA levels, Gleason score, perineural infiltration, number and percent of biopsy positive on pathology (60-65). Thus the World Health Organization (WHO) and other consensus groups have divided patients into groups based on these risk factors as shown in Table I (64) . Undoubtedly, in the future, further risk stratifications will be available guiding therapy toward maximum efficiency while minimizing the effects on quality of life. Patients with low risk presentation (Gleason score <6 and PSA <10ng/ml) but with more than 50% of biopsies positive should be treated with external beam radiation and brachytherapy.
We have evaluated the impact of the percent biopsies in predicting the biochemical outcome in patients treated with combination of XRT and brachytherapy for clinically localized prostate cancer (62). 105 patients were treated with combined therapy with either I-125 or Pd-103 seeds. Percent positive biopsies were determinable in 86 patients. Patients were divided into 3 risk groups based on the pretreatment PSA and Gleason score. Group A (n=33) included patients with unfavorable features (base involvement, multiple cores positive or perineural invasion). Group B (n=30) included patients with PSA less than 10ng/ml and Gleason score >7. Patients with PSA >than 10ng/ml were included in group C (n=23).
Patients were then stratified according to the percentage of the positive biopsies into <50% and >50%. Median pretreatment PSA was 7.2ng.ml (range: 2-44ng/ml). The clinical stage for these patients was: T1c, 61 patients; T2a, 20 patients; and T2b, 5 patients. PSA relapse free survival was based on the ASTRO consensus panel definition. Kaplan-Meier survival curves were used to assess the various prognostic factors. The median follow-up was 27 months (range: 13-73 months). The overall actuarial biochemical relapse free survival at 5 years for 86 analyzed patients was 85% with a median follow-up PSA at last follow-up of 0.4ng/ml. The biochemical relapse free survival for groups A, B and C are 100%, 80% and 78%, respectively ( Fig. 9) . No difference was observed in the outcome among the various sub groups stratified according to the percentage positive biopsies. The median follow-up PSA at last follow-up was 0.5ng/ml for patients with <50% positive biopsies and 0.4ng/ml PSA for patients with >50% positive biopsies. A more detailed report on our 10 years experience with prostate brachytherapy is under preparation for publication.
There is room for further refinements in planning, implantation, post-implant dosimetry and in understanding the correlation between dosimetric parameters and clinical out come and normal tissue complications. Recent advances such as image fusion between TRUS and fluoroscopy, TRUS and CT, CT and MRI and SPECT (single photon emission computed tomography) have the potential to improve our ability to better delineate the structures of interest, including the extent of the tumor, both pre-and post-implantation, leading to more Figure 9 : Pre-treatment PSA and Gleason score vs. % biochemical relapse free survival for patients treated with external beam radiation therapy (EBRT) + brachytherapy (BRT). Group A (n=33), pre treatment PSA <10 ng/ml and Gleason score <6 with unfavorable features with prostate base +, or multiple cores + (50%) or with peri-neural invasion. Group B (n=30), patients with PSA < 10 ng/ml with a Gleason score >7. Group C (n=23), Patients with any Gleason score and PSA > 10 ng/ml (62). precise dosimetric evaluation for target and normal tissues (25, 28, 29, 47, (51) (52) (53) 66) . One of the major purpose of the image fusion is to superimpose functional (biochemical, pharmacologic and physiologic) information, usually obtained from SPECT, PET scans onto underlying anatomic structures depicted on MR images or CT scans. Clinical applications include diagnosis, surgery planning, radiation therapy planning, and assessment of disease progression or regression (66). Magnetic Resonance spectroscopy (MRS) detects metabolic activity and differentiate normal prostate from cancerous prostate tissue based on the ratios of creatine, choline and citrate production and consumption (67-68). MRS has been used with MRI to increase the accuracy of radiographic assessment of the tumor extent. The addition of metabolic information from 3D MRS imaging to anatomical data from MRI and CT would provide better detection and localization of prostate cancer (67). Combining MRI, MRS and CT data can be used to selectively escalate the dose by intensity-modulated brachytherapy, i.e., implanting the biologically active regions with higher activities. The feasibility of such an approach has been shown in the treatment of prostate cancer with IMRT, where multiple dominant intraprostatic lesions have been treated to a dose of 90 Gy while the remaining prostate has been treated to 75.6 Gy (69-70).
